Two weeks after securing more than $46 million in financing, Visterra struck a deal worth up to $1 billion with startup Vir Biotechnology.
AstraZeneca forged a research collaboration with Boston-based Berg, a specialist in artificial intelligence for drug hunting.
GV has invested in a company called SpyBiotech, which focuses on a so-called “super glue” that combines two parts of the bacteria that causes strep throat.
Elon Musk, the visionary behind SpaceX and Tesla, launched a new venture called Neuralink – a company that hopes to link humans with artificial intelligence.
Medical startups must successfully mix entrepreneurial knowledge, a STEM-steeped education, and real-life experience to have the type of lasting impact they desire.
February 19, 2016By Mark Terry, BioSpace.com Breaking News Staff Cambridge, Mass.-based venture capital firm Atlas Venture launched another Cambridge biotech startup yesterday, AvroBio. No financial details were disclosed. The company is founded on two novel cell and gene therapies that came out of the laboratories of Christopher Paige and Jeffrey Medin at the University […]
11 billion euro R&D programme through 2020, with 5 billion euro dedicated to pre-clinical R&D and 1.5 billion euro planned for cooperation with external partners New partnerships with the Icahn School of Medicine at Mount Sinai, Massachusetts General Hospital, the Scripps Research Institute and Weill Cornell Medicine to discover new treatments for inflammatory bowel […]
Nestle, famous for its coffee and chocolate, is stepping up investment in nutritional therapy, a business it believes will eventually generate annual sales of 10 billion Swiss francs ($10.5 billion). Greg Behar, chief executive of Nestle Health Science, told Reuters that the unit formed in 2011 already had revenue of more than 2 billion […]
Valeant Pharmaceuticals International Inc (VRX.TO) (VRX.N), under fire for price increases of its two heart drugs, said it was subpoenaed by U.S. prosecutors on its pricing, drug distribution and patient assistance programs. Valeant’s U.S.-listed shares were down 9 percent at $156.53 in premarket trading on Thursday. The company, which came under attack from Democratic lawmakers […]
MD Anderson Cancer Center, located in Houston, Texas, announced yesterday that together with Seattle-based Theraclone Sciences, Inc., it was launching an immuno-oncology antibody discovery company, OncoResponse. In addition, OncoResponse closed a Series A financing round worth $9.5 million, co-led by ARCH Venture Partners, Canaan Partners and MD Anderson. Also participating were William Marsh Rice University […]